Form 4: Edgewise Therapeutics CFO R. Michael Carruthers Reports Stock Transactions
SEC Form 4 Filing
R. Michael Carruthers, CFO of Edgewise Therapeutics, reports the acquisition and disposal of company stock, including shares sold to cover tax obligations related to vesting restricted stock units.
Summary
- R. Michael Carruthers, the Chief Financial Officer of Edgewise Therapeutics, Inc. (EWTX), reported transactions involving the company's common stock.
- On May 1, 2024, Carruthers acquired 5,208 shares of common stock at $0.00.
- These shares were acquired through the vesting of Restricted Stock Units (RSUs).
- On May 2, 2024, Carruthers sold 2,157 shares at an average price of $18.91.
- The sale was to cover statutory tax withholding obligations related to the vesting of RSUs.
- Following these transactions, Carruthers directly owns 35,230 shares of Edgewise Therapeutics common stock and 5,209 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock transactions.
Positives
- The vesting of RSUs indicates that performance milestones or time-based vesting requirements have been met.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of company leadership.
Key Dates
| Date | Description |
|---|---|
| 05/15/2023 | 2,898 shares purchased on May 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| 11/15/2023 | 257 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| 05/01/2023 | RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. |
| 05/01/2024 | Carruthers acquired 5,208 shares of common stock through RSU vesting. |
| 05/02/2024 | Carruthers sold 2,157 shares to cover tax obligations. |
| 05/03/2024 | Date of report. |
| 05/01/2032 | Expiration date of derivative security. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.